Most dogs diagnosed with bone cancer (osteosarcoma) survive about two months without any treatment. With the standard combination of surgery and chemotherapy, that number extends to roughly 10 to 12 months. These timelines vary significantly depending on the tumor’s location, your dog’s bloodwork results, and the treatment path you choose.
Survival Without Treatment
If no treatment is pursued, the average survival time is approximately two months from diagnosis. This short window is driven primarily by pain at the tumor site rather than the cancer spreading to other organs. The tumor weakens the bone, and as it grows, it causes worsening lameness and discomfort that eventually becomes unmanageable. Pain medications can help for a period, but without addressing the tumor itself, quality of life deteriorates quickly.
Survival With Surgery and Chemotherapy
The standard treatment for bone cancer in a limb is amputation followed by chemotherapy. In a study of 30 dogs, those treated with amputation plus chemotherapy survived a median of 290 days (about 9.5 months), with 13 of 15 dogs in the chemotherapy group surviving longer than six months and five surviving more than a year. One dog in the study was still alive at three years. Dogs treated with amputation alone had significantly shorter survival times.
These numbers reflect the central challenge of osteosarcoma: the primary tumor in the bone is usually manageable, but the cancer spreads to the lungs early and aggressively. By the time of diagnosis, microscopic spread to the lungs has often already occurred, even when chest X-rays look clean. Chemotherapy targets those invisible clusters of cancer cells, which is why it meaningfully extends survival compared to surgery alone.
Despite treatment, long-term survival remains uncommon. A study of 90 dogs with advanced osteosarcoma found one-year survival rates of just 6.6%, two-year rates of 4.7%, and three-year rates of 3.5%. Some dogs do beat those odds, but osteosarcoma is one of the most aggressive cancers in veterinary medicine.
Where the Tumor Is Matters
Not all bone cancers carry the same prognosis. According to the AKC Canine Health Foundation, tumors of the lower jaw and shoulder blade carry the best outcomes, with a median survival around 18 months. Tumors in the limbs (the most common location) fall in the middle at roughly 11 months. Tumors in the spine or skull are more difficult to treat and carry a median survival of about six months. The rarest form, where osteosarcoma develops in soft tissue outside the skeleton, has the shortest outlook at around two months.
Palliative Care Options
For dogs that aren’t good candidates for surgery, or when owners choose not to pursue amputation, palliative radiation therapy can significantly improve comfort. Between 74% and 96% of dogs experience some degree of pain relief after radiation, with improvement in limb function typically visible within 11 to 15 days. That pain relief lasts a median of roughly two to four months.
Dogs receiving palliative radiation survive a median of 4 to 10 months, a meaningful improvement over the two-month average with no treatment at all. Bone-strengthening medications (bisphosphonates) can also help manage pain from the tumor and are generally well tolerated. This approach focuses on keeping your dog comfortable and mobile for as long as possible rather than trying to cure the cancer.
Bloodwork as a Predictor
One of the most useful prognostic tools is a simple blood test measuring alkaline phosphatase, a liver and bone enzyme that tends to rise when osteosarcoma is active. Dogs with normal levels before treatment survived a median of 12.5 months, while dogs with elevated levels survived a median of 5.5 months. When veterinarians looked specifically at the bone-specific form of this enzyme, the gap was even wider: 16.6 months for normal levels versus 9.5 months for elevated levels.
This doesn’t change the treatment approach, but it gives you a clearer picture of what to expect. If your vet mentions alkaline phosphatase levels during the workup, this is why it matters.
Newer Immunotherapy Approaches
An emerging treatment combines a personalized cancer vaccine made from the dog’s own tumor cells with immune cell therapy. In a published study, dogs treated with this protocol (without traditional chemotherapy) had a median survival of 415 days, roughly 14 months. Five of the dogs in the study survived beyond two years, and one dog that developed skin metastasis experienced a complete spontaneous remission.
Side effects were minimal once researchers adjusted the protocol with pre-medications. While these results are promising compared to historical averages, the therapy is not yet widely available and needs further study. It does suggest that immunotherapy may eventually offer a meaningful alternative or addition to the current standard of care.
Signs the Cancer Is Progressing
Because osteosarcoma so frequently spreads to the lungs, the signs of progression are often respiratory. You may notice your dog breathing faster at rest, developing a persistent cough, tiring quickly on walks, or losing interest in food. At the primary site, increasing swelling, a return of lameness after a period of improvement, or obvious pain when the area is touched all suggest the tumor is advancing.
Veterinarians typically recommend chest X-rays every two to three months after treatment to monitor for visible lung metastasis. By the time respiratory symptoms appear, the spread is usually extensive. Weight loss, lethargy, and withdrawal from normal activities are common late-stage signs that many owners recognize as a shift in their dog’s overall well-being.